Fig. 4

RHM exerts anti-MM activity in vivo. A. In vivo growth of NCI-H929 xenografts treated with RHM (200 μg/kg and 400 μg/kg) or vehicle. Treatment was administered daily ip. Left panel: averaged tumor volume of each group ± SD is shown. *p < 0.05. Right panel: survival curves (Kaplan–Meier) of each group (log- rank test, *p < 0.05). Survival was evaluated from the first day of treatment until death or sacrifice. Percentage of mice alive is shown. C. Left panel: IHC analysis (40x) from a representative H929 xenograft per group (vehicle and RHM 400 μg/kg) for Ki67 and H&E expression. Right panel: Immunoblot of p-H2AX, cleaved-caspase-3, cleaved-PARP1 in lysates from a representative NCI-H929 xenograft per group (vehicle and RHM 400 μg/kg). GAPDH was used as a loading control